Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941664 | 0.97 | ACACB (0.42) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5746992 | 0.89 | PDE4B (0.37) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3941671 | 0.80 | ALDH1A1 (0.41) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3943880 | 0.77 | ACACB (0.41) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3946740 | 0.77 | ALDH1A1 (0.41) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3236478 | 0.75 | ACACB (0.42) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3941652 | 0.75 | ACACB (0.44) | ACACBPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL524383 | 0.73 | AR (0.55) | ALDH1A1MAPTSMN1; SMN2GAAHPGD | |
| SCHEMBL16956005 | 0.73 | SMN1; SMN2 (0.40) | ACACBACHEALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3662959 | 0.73 | ALDH1A1 (0.43) | ACACBPDE4BACHEALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557118-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2009-07-07 | — | — | US | disclosed |
| US-7122673-B2 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-10-17 | — | — | US | disclosed |
| EP-1621533-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2006-02-01 | — | — | EP | disclosed |
| EP-0981517-B1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES | UNIV AUSTRALIAN (AU) | 2005-11-16 | — | — | EP | disclosed |
| US-20050154004-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2005-07-14 | — | — | US | disclosed |
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | AUSTRALIAN NATIONAL UNIVERSITY, THE (AU) | 2003-11-06 | — | — | US | disclosed |
| US-6521757-B1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2003-02-18 | — | — | US | disclosed |
| EP-0981517-A4 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2001-01-24 | — | — | EP | disclosed |
| EP-0981517-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050365-A9 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | UNIV AUSTRALIAN (AU) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998050365-A1 | PREPARATION OF FUSED POLYCYCLIC ALKALOIDS BY RING CLOSURE OF AZOMETHINE YLIDES, NOVEL COMPOUNDS THEREOF AND THEIR USE AS CHEMOTHERAPEUTIC AGENTS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208076-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | HCCS, CYCS, CCNO | ACACB 2703/4885PDE4B 4644/4885PDE4A 4565/4885 |
| US-20050154004-A1 | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | HCCS, CYCS, CCNO | ACACB 2339/4885PDE4B 4628/4885PDE4A 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.